ALK and non-small cell lung carcinoma: For most of the ALK-positive NSCLC patients with brain involvement, surveillance using brain magnetic resonance imaging (MRI) is considered the preferable option; SRT may be offered at progression, even on the most potent, third-generation ALK TKI lorlatinib, while the use of the neurotoxic WBRT should be strongly discouraged for ALK-positive NSCLC, as long as potentially effective systemic treatments are still available [62].